Subscribe to Canada Free Press for FREE

Prof. Raphael Mechoulam, ‘father’ of medical cannabis, turns focus on asthma at Hebrew University’s Multidisciplinary Center on Cannabis Research.

Compound in cannabis could ease asthma


By —— Bio and Archives--November 9, 2017

Comments | Print Friendly | Subscribe | Email Us

Compound in cannabis could ease asthma
Hebrew University Prof. Raphael Mechoulam, known as the “father” of the medical cannabis industry, will lead a team investigating the benefits of non-psychoactive cannabis components for treating asthma and other respiratory conditions.

In 1964, Mechoulam, was the first scientist to successfully isolate the THC component in cannabis. He was then a young researcher at Israel’s Weizmann Institute of Science.

Hebrew University Prof. Raphael Mechoulam, known as the “father” of the medical cannabis industry, will lead a team investigating the benefits of non-psychoactive cannabis components for treating asthma and other respiratory conditions.

In 1964, Mechoulam, was the first scientist to successfully isolate the THC component in cannabis. He was then a young researcher at Israel’s Weizmann Institute of Science.

Of the 140 cannabinoid molecules in the cannabis plant, the two main components are THC (the psychoactive component) and CBD, which has anti-inflammatory properties. CBD is the focus of much of Israel’s burgeoning medical cannabis research on diabetes, heart disease, autism, fracture healing and inflammatory bowel disease.

Mechoulam will conduct studies on CBD and asthma together with Prof. Francesca Levi-Schaffer at the Hebrew University’s recently established Multidisciplinary Center on Cannabis Research. The research has been commissioned by CIITECH, a UK-Israeli biotech startup headed by Clifton Flack, who cofounded iCAN-Israel Cannabis. The latter is beginning clinical testing on a cannabis formulation for insomnia.

Allergic diseases including asthma, allergic rhinitis, atopic dermatitis and food allergies affect approximately 20 percent of the global population.

Mechoulam’s asthma research aim is to identify “a possible inhibitory effect of a derivative of cannabidiol (CBD) on allergic airway inflammation.”—More…



ISRAEL21c -- Bio and Archives | Comments

ISRAEL21c was founded in 2001, in the wake of the Second Intifada, to broaden public understanding of Israel beyond typical portrayals in the mainstream media.

The organization’s founders – Israeli-American technology executives – understood the great power of the Internet and developed a first-of-its kind online product with global appeal and reach.

Commenting Policy

Please adhere to our commenting policy to avoid being banned. As a privately owned website, we reserve the right to remove any comment and ban any user at any time.

Comments that contain spam, advertising, vulgarity, threats of violence, racism, anti-Semitism, or personal or abusive attacks on other users may be removed and result in a ban.
-- Follow these instructions on registering: